Please login to the form below

Not currently logged in
Email:
Password:

Endocyte appoints Parexel's Scot Harper to oversee clinical trials

He also previously served at Novartis and Lilly

Scot Harper, Endocyte Endocyte has appointed Dr Scot Harper as VP, clinical operations, where he will be responsible for clinical trial operations at the US biopharma company.

Dr Harper (pictured right) joins from clinical research organisation (CRO) Parexel, where he held the role of global portfolio director for oncology, overseeing clinical activities for cancer drugs from phase I to IV development.

He also has experience working in clinical operations for major pharma companies, serving as VP of Novartis' North American clinical operations, and senior director of clinical operations at Lilly.

Prior to this, Dr Harper worked in new product development at SmithKline Beechham.

Endocyte, which focuses on developing therapies for the treatment of cancer and other serious diseases, will benefit from his experience of working on the development of major oncology brands like Tasigna and Gleevec.

“Scot has deep expertise in the drug development process and management of all stages of clinical trials, and he will play a key role at Endocyte as we seek to expand and advance our platform,” said Ron Ellis, Endocyte's president and CEO, referencing the development of oncology candidates vintafolide and etarfolatide, which are in phase III and phase II trials respectively.

In addition, Endocyte says it has three new drug candidates scheduled to enter the clinic before the end of 2014.

9th May 2013

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Escaping the spin cycle of sub-optimal launch
...

Infographics